[A case of relapsed small-cell lung cancer successfully treated by administration of amrubicin].
Cardiotoxicity is a known adverse reaction of high cumulative doses of anthracycline drugs. We encountered a case successfully treated without myocardial disorder. A 54-year-old man who had been given a diagnosis of small-cell lung cancer (SCLC) (extensive disease) was treated with cisplatin (CDDP) plus irinotecan (CPT-11) as first-line chemotherapy, followed by amrubicin (AMR) (30 mg/m2) for 3 consecutive days against the relapsed SCLC. The cumulative dose reached 1110 mg/m2. This case report suggests that repeated treatment with AMR may be effective for relapsed SCLC.
Mori
Hidenori
H
Department of Respiratory Medicine, Gifu Red Cross Hospital.
Tanaka
Haruhito
H
D018943:Anthracyclines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D018943:Anthracyclines; D000970:Antineoplastic Agents; C055866:amrubicin